misonneh's breast [at least 200 articles] Export

Recent papers added to misonneh's library classified by the tag breast. You can also see everyone's breast.

	Genetic matters of CYP2D6 in breast cancer: copy number variations and nucleotide polymorphisms [My Copy] Nat Rev Cancer, Vol. 9, No. 11. (23 October 2009), pp. 842-843. by Ke-Da Yu, Zhi-Ming Shao posted to tamoxifen review pharmacogenetics genetics cyp2d6 comments breast by misonneh on 2009-11-19 05:26:25 as
	Genomics: We are individuals [My Copy] Nat Rev Cancer, Vol. 9, No. 11. (01 November 2009), pp. 770-771. by Gemma K. Alderton posted to technology subtypes pharmacogenetics metastasis genetics dynamic comments breast biomarker by misonneh on 2009-11-19 02:18:41 as
	Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. [My Copy] Nature, Vol. 461, No. 7265. (8 October 2009), pp. 809-813. by Sohrab P. Shah, Ryan D. Morin, Jaswinder Khattra, et al.Leah Prentice, Trevor Pugh, Angela Burleigh, Allen Delaney, Karen Gelmon, Ryan Guliany, Janine Senz, Christian Steidl, Robert A. Holt, Steven Jones, Mark Sun, Gillian Leung, Richard Moore, Tesa Severson, Greg A. Taylor, Andrew E. Teschendorff, Kane Tse, Gulisa Turashvili, Richard Varhol, René L. Warren, Peter Watson, Yongjun Zhao, Carlos Caldas, David Huntsman, Martin Hirst, Marco A. Marra, Samuel Aparicio posted to subtypes genetics dynamic breast by misonneh on 2009-11-19 02:06:54 as along with 13 people and 2 groups pst jwfoley stubrown chvlyl giovenko frohike brianb Zephyrus jsuchit mkiyer torfinnnome merpublic djkt Chinnaiyan Lab Journal picks
	Molecular epidemiology of genetic polymorphisms in estrogen metabolizing enzymes in human breast cancer. [My Copy] Journal of the National Cancer Institute. Monographs, No. 27. (2000), pp. 125-134. by P. A. Thompson, C. Ambrosone posted to risk review metabolism genetics estrogen epidemiology breast by misonneh on 2009-11-15 16:36:07 as
	Breast cancer: critical data analysis concludes that estrogens are not the cause, however lifestyle changes can alter risk rapidly. [My Copy] Journal of clinical epidemiology, Vol. 57, No. 8. (August 2004), pp. 766-772. by Richard A. Wiseman posted to review reproductive prenatal lifestyle epidemiology dynamic breast by misonneh on 2009-11-15 16:20:37 as along with 1 person Zephyrus
	Intrauterine factors and risk of breast cancer: a systematic review and meta-analysis of current evidence. [My Copy] The lancet oncology, Vol. 8, No. 12. (December 2007), pp. 1088-1100. by Fei Xue, Karin B. Michels posted to review meta_analysis intrauterine epidemiology breast by misonneh on 2009-11-15 16:08:27 as
	Exploring the underlying hormonal mechanisms of prenatal risk factors for breast cancer: a review and commentary. [My Copy] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, Vol. 16, No. 9. (1 September 2007), pp. 1700-1712. by Rebecca Troisi, Nancy Potischman, Robert N. Hoover posted to review moa intrauterine epidemiology breast by misonneh on 2009-11-15 16:07:46 as along with 1 person and 2 groups Zephyrus R.E.A.D Breast Cancer Reading Club
	Basal-like breast cancer: a critical review. [My Copy] Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 26, No. 15. (20 May 2008), pp. 2568-2581. by Emad A. Rakha, Jorge S. Reis-Filho, Ian O. Ellis posted to triple-negative review breast basal-like by misonneh on 2009-11-10 05:57:30 as along with 4 people and 1 group merpublic Zephyrus edwardli ruszczyk Breast Cancer Reading Club
	The Nottingham prognostic index for invasive carcinoma of the breast. [My Copy] Pathology oncology research : POR, Vol. 14, No. 2. (1 June 2008), pp. 113-115. by Andrew H. Lee, Ian O. Ellis posted to prognosis prediction index breast by misonneh on 2009-11-10 05:55:51 as along with 1 person Zephyrus
	MicroRNA involvement in the pathogenesis and management of breast cancer [My Copy] J Clin Pathol, Vol. 62, No. 5. (1 May 2009), pp. 422-428. by S. M. Khoshnaw, A. R. Green, D. G. Powe, I. O. Ellis posted to review pathology moa mirna breast by misonneh on 2009-11-10 05:49:29 as along with 2 people and 1 group tonamswish songpku microRNA
	Triple-negative/basal-like breast cancer: review. [My Copy] Pathology, Vol. 41, No. 1. (January 2009), pp. 40-47. by Emad A. Rakha, Ian O. Ellis posted to triple-negative review breast basal-like by misonneh on 2009-11-10 05:48:24 as along with 1 person Zephyrus
	Basal-like and Triple-Negative Breast Cancer: Definition and Therapeutic Insights - ASCO [My Copy] posted to triple-negative review breast basal-like by misonneh on 2009-11-10 05:44:25 as
	Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. [My Copy] Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 14, No. 5. (1 March 2008), pp. 1368-1376. by Maggie C. Cheang, David Voduc, Chris Bajdik, et al.Samuel Leung, Steven McKinney, Stephen K. Chia, Charles M. Perou, Torsten O. Nielsen posted to triple-negative subtypes hr her2 breast biomarker basal-like by misonneh on 2009-11-10 05:42:06 as along with 4 people songpku NaliniChilkov Zephyrus jfr
	The role of radiotracer imaging in the diagnosis and management of patients with breast cancer: part 2--response to therapy, other indications, and future directions. [My Copy] Journal of nuclear medicine : official publication, Society of Nuclear Medicine, Vol. 50, No. 5. (May 2009), pp. 738-748. by Jean H. Lee, Eric L. Rosen, David A. Mankoff posted to review pet perspective neoadjuvant kim_ chemotherapy breast by misonneh on 2009-11-10 05:17:50 as
	The Role of Radiotracer Imaging in the Diagnosis and Management of Patients with Breast Cancer: Part 1--Overview, Detection, and Staging [My Copy] J Nucl Med, Vol. 50, No. 4. (1 April 2009), pp. 569-581. by Jean H. Lee, Eric L. Rosen, David A. Mankoff posted to review prognosis pet diganosis detection breast by misonneh on 2009-11-10 05:16:56 as
	Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study. [My Copy] PloS one, Vol. 3, No. 7. (2008) by Martin Widschwendter, Sophia Apostolidou, Elke Raum, et al.Dietrich Rothenbacher, Heidi Fiegl, Usha Menon, Christa Stegmaier, Ian J. Jacobs, Hermann Brenner posted to polycomb peripheral_blood methylation hr gene_specific_methylation epigenetics breast association by misonneh on 2009-11-04 21:44:12 as
	Methylated NEUROD1 promoter is a marker for chemosensitivity in breast cancer. [My Copy] Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 14, No. 11. (1 June 2008), pp. 3494-3502. by Heidi Fiegl, Allison Jones, Cornelia Hauser-Kronberger, et al.Georg Hutarew, Roland Reitsamer, Robin L. Jones, Mitch Dowsett, Elisabeth Mueller-Holzner, Gudrun Windbichler, Günter Daxenbichler, Georg Goebel, Christian Ensinger, Ian Jacobs, Martin Widschwendter posted to response prediction pharmacogenetics neurod1 neoadjuvant methylation gene_specific_methylation epigenetics circ_dna chemotherapy breast by misonneh on 2009-11-04 21:21:37 as
	Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors. [My Copy] British journal of cancer, Vol. 101, No. 8. (20 October 2009), pp. 1253-1260. by M. Hauglid Flågeng, Haugan L. Moi, J. M. Dixon, et al.J. Geisler, E. A. Lien, W. R. Miller, P. E. Lønning, G. Mellgren posted to response prediction nuclear_receptor neoadjuvant kim_ her2 expression breast aromatase_inhibitor by misonneh on 2009-11-03 06:03:37 as
	The effect of genetic variability on drug response in conventional breast cancer treatment. [My Copy] European journal of pharmacology (18 October 2009) by Emilia Wiechec, Lise Lotte L. Hansen posted to review response pharmacogenetics metabolism genetics chemotherapy breast by misonneh on 2009-10-29 07:12:29 as
	Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. [My Copy] Cancer, Vol. 115, No. 5. (1 March 2009), pp. 952-961. by Masatsugu Okishiro, Tetsuya Taguchi, Seung Jin Kim, Kenzo Shimazu, Yasuhiro Tamaki, Shinzaburo Noguchi posted to tamoxifen pharmacogenetics cyp2d6 breast asian_populations by misonneh on 2009-10-27 07:17:16 as along with 2 people ilsun Mi-Seon
	Impact of CYP2D610 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. [My Copy] Cancer science*, Vol. 99, No. 5. (May 2008), pp. 995-999. by Kazuma Kiyotani, Taisei Mushiroda, Mitsunori Sasa, et al.Yoshimi Bando, Ikuko Sumitomo, Naoya Hosono, Michiaki Kubo, Yusuke Nakamura, Hitoshi Zembutsu posted to pharmacogenetics cyp2d6 breast asian_populations by misonneh on 2009-10-27 07:12:50 as
	Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. [My Copy] Journal of the National Cancer Institute, Vol. 95, No. 23. (3 December 2003), pp. 1758-1764. by Vered Stearns, Michael D. Johnson, James M. Rae, et al.Alan Morocho, Antonella Novielli, Pankaj Bhargava, Daniel F. Hayes, Zeruesenay Desta, David A. Flockhart posted to tamoxifen pk pharmacogenetics metabolism ddi breast by misonneh on 2009-10-27 07:02:30 as
	CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. [My Copy] Journal of the National Cancer Institute, Vol. 97, No. 1. (5 January 2005), pp. 30-39. by Yan Jin, Zeruesenay Desta, Vered Stearns, et al.Bryan Ward, Herbert Ho, Kyung-Hoon H. Lee, Todd Skaar, Anna Maria M. Storniolo, Lang Li, Adjei Araba, Rebecca Blanchard, Anne Nguyen, Lynda Ullmer, Jill Hayden, Suzanne Lemler, Richard M. Weinshilboum, James M. Rae, Daniel F. Hayes, David A. Flockhart posted to tamoxifen pharmacogenetics genetics ddi cyp2d6 breast by misonneh on 2009-10-27 07:01:49 as along with 1 person frohike
	Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. [My Copy] Clinical pharmacology and therapeutics, Vol. 80, No. 1. (July 2006), pp. 61-74. by Silvana Borges, Zeruesenay Desta, Lang Li, et al.Todd C. Skaar, Bryan A. Ward, Anne Nguyen, Yan Jin, Anna Maria M. Storniolo, D. Michele Nikoloff, Lin Wu, Grant Hillman, Daniel F. Hayes, Vered Stearns, David A. Flockhart posted to tamoxifen pk pharmacogenetics metabolism cyp2d6 breast by misonneh on 2009-10-27 07:01:06 as
	Germline pharmacogenetics of tamoxifen response: have we learned enough? [My Copy] Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 25, No. 33. (20 November 2007), pp. 5147-5149. by Zeruesenay Desta, David A. Flockhart posted to tamoxifen pharmacogenetics genetics cyp2d6 comments breast by misonneh on 2009-10-27 06:59:30 as
	Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen [My Copy] JAMA, Vol. 302, No. 13. (7 October 2009), pp. 1429-1436. by Werner Schroth, Matthew P. Goetz, Ute Hamann, et al.Peter A. Fasching, Marcus Schmidt, Stefan Winter, Peter Fritz, Wolfgang Simon, Vera J. Suman, Matthew M. Ames, Stephanie L. Safgren, Mary J. Kuffel, Hans U. Ulmer, Julia Bolander, Reiner Strick, Matthias W. Beckmann, Heinz Koelbl, Richard M. Weinshilboum, James N. Ingle, Michel Eichelbaum, Matthias Schwab, Hiltrud Brauch posted to tamoxifen prognosis prediction pharmacogenetics genotype cyp2d6 breast by misonneh on 2009-10-26 06:36:40 as along with 2 people songpku merpublic
	Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy. [My Copy] Breast cancer research and treatment, Vol. 115, No. 3. (June 2009), pp. 643-650. by Adedayo A. Onitilo, Catherine A. McCarty, Russell A. Wilke, et al.Ingrid Glurich, Jessica M. Engel, David A. Flockhart, Anne Nguyen, Lang Li, Deming Mi, Todd C. Skaar, Yan Jin posted to tamoxifen pharmacogenetics hr genetics breast adr by misonneh on 2009-10-21 02:21:36 as
	Multiparity and the risk of premenopausal breast cancer: different effects across ethnic groups in Singapore. [My Copy] Breast cancer research and treatment, Vol. 113, No. 3. (February 2009), pp. 553-558. by Helena M. Verkooijen, Karen P. Yap, Vineta Bhalla, Khuan Yew Y. Chow, Kee Seng S. Chia posted to risk_factor race parity hormone estrogen epidemiology breast by misonneh on 2009-10-21 01:30:03 as
	Do Asian breast cancer patients have poorer survival than their western counterparts? A comparison between Singapore and Stockholm. [My Copy] Breast cancer research : BCR, Vol. 11, No. 1. (24 January 2009), R4. by Benita Kiat Tee K. Tan, Gek Hsiang H. Lim, Kamila Czene, Per Hall, Kee Seng S. Chia posted to trend survival prognosis epidemiology breast asian_populations by misonneh on 2009-10-21 01:27:20 as
	CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer. [My Copy] Breast cancer research : BCR, Vol. 9, No. 6. (17 December 2007), R87. by Francisco J. Esteva, Jing Wang, Feng Lin, et al.Jaime A. Mejia, Kai Yan, Kadri Altundag, Vicente Valero, Aman U. Buzdar, Gabriel N. Hortobagyi, W. Fraser Symmans, Lajos Pusztai posted to response prediction neoadjuvant immunity her2 breast biomarker by misonneh on 2009-10-19 08:49:42 as
	Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. [My Copy] Journal of the National Cancer Institute, Vol. 100, No. 3. (6 February 2008), pp. 207-212. by Giuseppe Viale, Meredith M. Regan, Mauro G. Mastropasqua, et al.Fausto Maffini, Eugenio Maiorano, Marco Colleoni, Karen N. Price, Rastko Golouh, Tiziana Perin, R. W. Brown, Anikó Kovács, Komala Pillay, Christian Ohlschlegel, Barry A. Gusterson, Monica Castiglione-Gertsch, Richard D. Gelber, Aron Goldhirsch, Alan S. Coates, International Breast Cancer Study Group posted to prognosis prediction ki67 hormone chemotherapy breast biomarker by misonneh on 2009-10-19 08:47:32 as
	Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. [My Copy] Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 26, No. 8. (10 March 2008), pp. 1275-1281. by Cornelia Liedtke, Chafika Mazouni, Kenneth R. Hess, et al.Fabrice André, Attila Tordai, Jaime A. Mejia, W. Fraser Symmans, Ana M. Gonzalez-Angulo, Bryan Hennessy, Marjorie Green, Massimo Cristofanilli, Gabriel N. Hortobagyi, Lajos Pusztai posted to survival prognosis prediction neoadjuvant chemotherapy breast biomarker by misonneh on 2009-10-19 08:44:43 as
	Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance. [My Copy] Breast cancer research and treatment, Vol. 112, No. 3. (9 December 2008), pp. 475-488. by Djuana M. Harvell, Nicole S. Spoelstra, Meenakshi Singh, et al.James L. McManaman, Christina Finlayson, Tzu Phang, Susan Trapp, Lawrence Hunter, Wendy W. Dye, Virginia F. Borges, Anthony Elias, Kathryn B. Horwitz, Jennifer K. Richer posted to resonse resistance neoadjuvant hormone chemotherapy breast biomarker by misonneh on 2009-10-19 08:44:01 as along with 1 person jfr
	Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. [My Copy] Breast cancer research : BCR, Vol. 10, No. 2. (01 April 2008), R30. by Gunter von Minckwitz, Hans-Peter P. Sinn, Günter Raab, et al.Sibylle Loibl, Jens-Uwe U. Blohmer, Holger Eidtmann, Jörn Hilfrich, Elisabeth Merkle, Christian Jackisch, Serban D. Costa, Angelika Caputo, Manfred Kaufmann, German Breast Group posted to response neoadjuvant dynamic chemotherapy breast biomarker by misonneh on 2009-10-19 08:42:21 as
	The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. [My Copy] Breast cancer research and treatment, Vol. 116, No. 1. (1 July 2009), pp. 53-68. by Robin L. Jones, Janine Salter, Roger A'Hern, et al.Ash Nerurkar, Marina Parton, Jorge S. Reis-Filho, Ian E. Smith, Mitchell Dowsett posted to prediction neoadjuvant dynamic chemotherapy breast biomarker by misonneh on 2009-10-19 08:39:43 as along with 1 person Zephyrus
	Changes in tumour biological markers during primary systemic chemotherapy (PST). [My Copy] Anticancer research, Vol. 28, No. 3B. (n 2008), pp. 1797-1804. by Hans Neubauer, Christian Gall, Ulrich Vogel, et al.Rene Hornung, Diethelm Wallwiener, Erich Solomayer, Tanja Fehm posted to response dynamic chemotherapy breast biomarker by misonneh on 2009-10-19 08:37:21 as
	Tumor-infiltrating lymphocytes predict response to neoadjuvant chemotherapy in patients with breast carcinoma. [My Copy] Cancer investigation, Vol. 26, No. 10. (December 2008), pp. 1024-1031. by Helena Hornychova, Bohuslav Melichar, Marketa Tomsova, Jindøiska Mergancova, Hana Urminska, Ales Ryska posted to response neoadjuvant immunity chemotherapy breast biomarker by misonneh on 2009-10-19 08:17:43 as
	Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. [My Copy] Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 26, No. 5. (10 February 2008), pp. 814-819. by Julie R. Gralow, Harold J. Burstein, William Wood, et al.Gabriel N. Hortobagyi, Luca Gianni, Gunter von Minckwitz, Aman U. Buzdar, Ian E. Smith, William F. Symmans, Baljit Singh, Eric P. Winer posted to review response prognosis prediction neoadjuvant breast by misonneh on 2009-10-19 08:15:04 as
	Stromal matrix protein expression following preoperative systemic therapy in breast cancer. [My Copy] Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 15, No. 2. (15 January 2009), pp. 731-739. by Anna-Maria M. Tokes, Attila Marcell M. Szasz, Andrea Farkas, et al.Adrienn Ildiko I. Toth, Magdolna Dank, Laszlo Harsanyi, Bela Akos A. Molnar, Istvan Arthur A. Molnar, Zsolt Laszlo, Zoltan Rusz, Janina Kulka posted to stromal_component response neoadjuvant expression chemotherapy breast by misonneh on 2009-10-19 08:13:43 as
	Supervised risk predictor of breast cancer based on intrinsic subtypes. [My Copy] Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 27, No. 8. (10 March 2009), pp. 1160-1167. by Joel S. Parker, Michael Mullins, Maggie C. Cheang, et al.Samuel Leung, David Voduc, Tammi Vickery, Sherri Davies, Christiane Fauron, Xiaping He, Zhiyuan Hu, John F. Quackenbush, Inge J. Stijleman, Juan Palazzo, J. S. Marron, Andrew B. Nobel, Elaine Mardis, Torsten O. Nielsen, Matthew J. Ellis, Charles M. Perou, Philip S. Bernard posted to time_to_event subtypes risk_assessment response prognosis prediction genetics breast by misonneh on 2009-10-19 08:08:31 as along with 2 people ptrobajo jfr
	Should histologic type be taken into account when considering neoadjuvant chemotherapy in breast carcinoma? [My Copy] The breast journal, Vol. 15, No. 2. (r 2009), pp. 146-154. by Peggy S. Sullivan, Sophia K. Apple posted to response neoadjuvant histology chemotherapy breast by misonneh on 2009-10-19 08:04:25 as
	Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. [My Copy] Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 15, No. 12. (15 June 2009), pp. 4234-4241. by Tomonori Tanei, Koji Morimoto, Kenzo Shimazu, et al.Seung Jin J. Kim, Yoshio Tanji, Tetsuya Taguchi, Yasuhiro Tamaki, Shinzaburo Noguchi posted to response resistance neoadjuvant kim_ expression chemotherapy breast aldh1 by misonneh on 2009-10-19 07:55:29 as
	Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy. [My Copy] The oncologist, Vol. 13, No. 12. (December 2008), pp. 1235-1245. by Frédérique Penault-Llorca, Catherine Abrial, Inès Raoelfils, et al.Philippe Chollet, Anne Cayre, Marie-Ange A. Mouret-Reynier, Emilie Thivat, Florence Mishellany, Pierre Gimbergues, Xavier Durando posted to response neoadjuvant expression chemotherapy breast biomarker by misonneh on 2009-10-09 08:42:24 as
	Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. [My Copy] Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 27, No. 16. (1 June 2009), pp. 2630-2637. by José Baselga, Vladimir Semiglazov, Peter van Dam, et al.Alexey Manikhas, Meritxell Bellet, José Mayordomo, Mario Campone, Ernst Kubista, Richard Greil, Giulia Bianchi, Jutta Steinseifer, Betty Molloy, Erika Tokaji, Humphrey Gardner, Penny Phillips, Michael Stumm, Heidi A. Lane, J. Michael Dixon, Walter Jonat, Hope S. Rugo posted to response neoadjuvant expression chemotherapy breast by misonneh on 2009-10-09 08:10:36 as
	Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. [My Copy] British journal of cancer, Vol. 92, No. 1. (17 January 2005), pp. 147-155. by R. J. Burcombe, A. Makris, P. I. Richman, et al.F. M. Daley, S. Noble, M. Pittam, D. Wright, S. A. Allen, J. Dove, G. D. Wilson posted to response neoadjuvant expression chemotherapy breast by misonneh on 2009-10-09 08:08:16 as
	Clinical and pathological response to primary chemotherapy in patients with locally advanced breast cancer grouped according to hormonal receptors, Her2 status, grading and Ki-67 proliferation index. [My Copy] Anticancer research, Vol. 29, No. 5. (May 2009), pp. 1621-1625. by Loredana Miglietta, Paola Vanella, Luciano Canobbio, Maria Angela A. Parodi, Pamela Guglielmini, Francesco Boccardo posted to response neoadjuvant expression chemotherapy breast by misonneh on 2009-10-09 08:03:47 as
	Variations in gene expression and response to neoadjuvant chemotherapy in breast carcinoma. [My Copy] Cancer investigation, Vol. 27, No. 5. (June 2009), pp. 521-528. by Romain Boidot, Frédérique Vegran, Marie-Sophie S. Soubeyrand, Pierre Fumoleau, Bruno Coudert, Sarab Lizard-Nacol posted to response neoadjuvant expression chemotherapy breast by misonneh on 2009-10-09 08:00:01 as
	Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer. [My Copy] Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 15, No. 14. (15 July 2009), pp. 4712-4721. by Chirayu Shah, Todd W. Miller, Shelby K. Wyatt, et al.Eliot T. McKinley, Maria Graciela G. Olivares, Violeta Sanchez, Donald D. Nolting, Jason R. Buck, Ping Zhao, M. Sib Ansari, Ronald M. Baldwin, John C. Gore, Rachel Schiff, Carlos L. Arteaga, H. Charles Manning posted to response pet neoadjuvant chemotherapy breast by misonneh on 2009-10-09 07:57:35 as
	StatBite Breast Cancer: 5-Year Survival Rates in U.S. for Selected Histologic Types by Stage [My Copy] J. Natl. Cancer Inst., Vol. 101, No. 19. (7 October 2009), 1303. posted to survival summary statistics prognosis breast by misonneh on 2009-10-07 02:06:19 as
	MicroRNAs as prognostic indicators and therapeutic targets: potential effect on breast cancer management. [My Copy] Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 14, No. 2. (15 January 2008), pp. 360-365. by Aoife J. Lowery, Nicola Miller, Roisin E. McNeill, Michael J. Kerin posted to review prognosis pharmacogenetics mirna breast by misonneh on 2009-10-06 20:13:54 as along with 1 person giovenko

Note: You may cite this page as: http://www.citeulike.org/user/misonneh/tag/breast

Result page: 1 2 3 4 5 Next

review	298
breast	249
genetics	159
epigenetics	155
methylation	147
pharmacogenetics	125
statistics	85
comments	63
biomarker	62
gene_specific_methylation	62
gwas	61
prognosis	60
tamoxifen	52
association	50
peripheral	47
gxe	46
chemotherapy	45
moa	44
diet	42
folate	38
modeling	38
guideline	35
resistance	35
global	33
meta_analysis	33
prediction	33
epidemiology	31
response	31
epistasis	30
adr	28
korean	28
survival	28
dynamic	27
diagnosis	26
haplotype	26
prostate	26
technology	26
cyp2d6	23
expression	23
time_to_event	23
circ_dna	21
colon	21
instability	21
neoadjuvant	21
environment	20
database	19
prevention	19
race	19
progression	18
lung	17
perspective	17
line1	16
pooling	16
therapy	16
immunity	14
risk_factor	14
clinic	13
hr	13
invivo	13
target_dna	13
tool	13
5mdc	12
age	12
randomized_controlled_trial	12
tutorial	12
1-carbon	11
gxg	11
hematology	11
metastasis	11
phenotype	11
pk	11
bladder	10
data_mining	10
mirna	10
estrogen	9
exposure	9
gst	9
hormone	9
smoking	9
bias	8
design	8
esr1	8
fda	8
heterogeneity	8
ivive	8
lifestyle	8
reproductive	8
cnv	7
dnmt	7
etiology	7
her2	7
hla	7
kim_	7
mdr1	7
metabolism	7
mthfr	7
pathway	7
power	7
prenatal	7
subtypes	7
trend	7
alcohol	6
cancer	6
carbamazepine	6
cell	6
cohort	6
cyp450	6
ddi	6
dna_repair	6
drug_discovery	6
epilepsy	6
histone	6
hyper_hypo	6
maternal	6
pcb	6
summary	6
system_biology	6
benign	5
cervix	5
chemoprevention	5
fundamental_concept_s1	5
inheritance	5
intervention	5
mgmt	5
mhc	5
microarray	5
nos3	5
pet	5
translation	5
array	4
asian_populations	4
balanced	4
basal-like	4
biobank	4
bmd	4
cimp	4
cns	4
detection	4
leukemia	4
linkage	4
methodology	4
mortality	4
ntissue	4
observation	4
pathology	4
refractory	4
transport	4
triple-negative	4
tsnp	4
aml	3
antioxidant	3
cluster	3
cyp1a1	3
cytokine	3
demethylation	3
fu	3
glioblastoma	3
hitchhiking	3
intrauterine	3
mds	3
metformin	3
molecular	3
public	3
ros	3
statin	3
sult1a1	3
sult1e1	3
swog	3
toxicity	3
validation	3
allergy	2
apoptosis	2
aromatase_inhibitor	2
aspirin	2
atm	2
bayesian	2
benzopyrene	2
bisphenol	2
brain	2
brca	2
brca12	2
caret	2
childhood	2
classification	2
consorcium	2
cyp2c19	2
cyp2e1	2
decitabine	2
definition	2
diabetes	2
egfr_pathway	2
endometrix	2
epigenetic_therapy	2
feature_selection	2
finasteride	2
fprp	2
genotype	2
hematopoiety	2
immortalization	2
insilico	2
irinotecan	2
iron	2
isoflavone	2
kawasaki	2
lymphoma	2
mnsod	2
nqo1	2
nutrition	2
oral	2
ovarian	2
ovary	2
parent_study	2
pharmacodynamic	2
phase	2
protocol	2
quantitative_traits	2
radiotherapy	2
risk_assessment	2
s8897	2
slco1b1	2
specimen	2
testicular	2
toxicology	2
ugt	2
wnt	2
abacavir	1
acs	1
aldh1	1
aldh2	1
alkylating_agents	1
alternative	1
anthracycline	1
antidepressant	1
assay	1
azacitidine	1
benzene	1
bmp	1
casp8	1
cat	1
catechol	1
cbr3	1
cdk	1
cell_cycle_control	1
cml	1
compliance	1
comt	1
confounder	1
consortium	1
cyclophosphamide	1
cyp19	1
cyp1a2	1
cyp1b1	1
cyp2c9	1
cyp3a4	1
dag	1
dcic	1
decision	1
diganosis	1
digoxin	1
ecadherin	1
endpoint	1
epidgenetics	1
example	1
family_hx	1
fastsnp	1
fmr1	1
fun	1
glioma	1
gpx1	1
heritability	1
hif1a	1
histology	1
history	1
hnscc	1
ho1	1
hogg1	1
hpv	1
illumina	1
immunoprecipitation	1
index	1
infection	1
inflammtion	1
integration	1
interleukin	1
invitro	1
ki67	1
lactation	1
lipidadjust	1
liver	1
maspin	1
mbd2	1
metabolomics	1
meternal	1
methotrexate	1
mining	1
mpo	1
mrp3	1
multiple_myeloma	1
multitest	1
myc	1
networking	1
neurod1	1
nhs	1
no	1
nrf2	1
nsaid	1
nuclear_receptor	1
obesity	1
oncotypedx	1
opg	1
oralscc	1
osteoporosis	1
outcome	1
p53	1
parity	1
paternal	1
pax2	1
peakbmd	1
peripheral_blood	1
pharmacogenomics	1
pharmacokinetic_variability	1
phytoestrogen	1
plink	1
polycomb	1
polymapr	1
polyphenol	1
practice	1
prevalence	1
proression	1
psychoses	1
qsar	1
rank	1
rcc	1
read_	1
resonse	1
rfc	1
risk	1
s100p	1
sat2	1
scn	1
series	1
sfrp5	1
silencing_rna	1
splicing	1
sputum	1
src	1
steroid	1
stromal_component	1
tea	1
temozolomide	1
tgf	1
tgm2	1
tp53	1
tpmt	1
twin_study	1
ugt1a1	1
warfarin	1
xpd	1
xrcc1	1
xrcc3	1

misonneh's breast [at least 200 articles] Export

misonneh's tags